Pharsight

Drugs that contain Vosoritide

1. Voxzogo patents expiration

VOXZOGO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8198242 BIOMARIN PHARM Variants of C-type natriuretic peptide
Jun, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48267 BIOMARIN PHARM Variants of C-type natriuretic peptide
May, 2030

(5 years from now)

US10646550 BIOMARIN PHARM Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Aug, 2036

(12 years from now)

US9907834 BIOMARIN PHARM Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Aug, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 19, 2026
Orphan Drug Exclusivity(ODE-449) Oct 20, 2030
New Patient Population(NPP) Oct 20, 2026
Orphan Drug Exclusivity(ODE-387) Nov 19, 2028

NCE-1 date: 19 November, 2025

Market Authorisation Date: 19 November, 2021

Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

VOXZOGO family patents

Family Patents